GlaxoSmithKline: Buy or Bye?
With all the recent news, is the London-based pharmaceutical giant a buy now?
This Is a Concern That Amgen Investors Shouldn't Take Lightly
Most investors are focused on the upcoming PDUFA decision for PCSK9 inhibitor Repatha, but this should be a far bigger concern.
3 Charts That Show Healthcare Stocks Should Stay Hot for Years to Come
These unstoppable trends mean plenty of healthcare stocks should keep soaring.